

October 25, 2016

Dear Valued Customer,

We have an important I 131 supply update to share with you. On August 30, 2016, Mallinckrodt Nuclear Medicine distributed a customer communication regarding the temporary suspension of our I 131 Therapy Capsules and Solution production. This suspension was set to begin after we released our production lot on Friday November 4, 2016.

Through the effort of our procurement team and the cooperation of one of our global suppliers we have secured I 131 through the end of calendar year 2016. We will have limited supply the week of November 11-17 but will return to full production levels starting Friday November 18. We will maintain full production levels through the end of 2016.

As mentioned in our previous letter we have worked diligently to validate another long-term I 131 source for 2017. We have completed this work and our ability to use this alternate source is now pending regulatory approval. It is possible we may experience a brief outage at the beginning of 2017. We continue to explore different options to prevent this from occurring. We will communicate more details with you as it gets closer to the new year.

For additional information, please contact your local Mallinckrodt Nuclear Medicine sales representative at 800.634.1515 or our Customer Service department at 888.744.1414.

Best Regards,



David M Koerber  
Senior Marketing Product Manager, North America